<a href="https://laohu8.com/S/ENLV">Enlivex Therapeutics Ltd.</a> Announces Date for Extraordinary General Meeting of Shareholders
Enlivex Therapeutics Ltd. has announced that it will hold an Extraordinary General Meeting of Shareholders on February 3, 2026, at its offices in Ness Ziona, Israel. During the meeting, shareholders will vote on several key proposals, including approving amendments to the Company’s Articles of Association. These amendments involve changing the Company’s name to “Enlivex Ltd.” or another name containing “Enlivex” as approved by management, classifying the Board of Directors into three classes with staggered three-year terms, and increasing the Company’s authorized share capital. Additional resolutions include approving amendments to the exemption and indemnification agreement for directors and the Chief Executive Officer, as well as the approval of an equity bonus in the form of restricted share units for the Chief Executive Officer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-123303), on December 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.